Last reviewed · How we verify
Placebo matching Dapaglifolzin
This is a placebo formulation designed to match dapagliflozin, an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption.
This is a placebo formulation designed to match dapagliflozin, an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption. Used for Placebo control for dapagliflozin clinical trials.
At a glance
| Generic name | Placebo matching Dapaglifolzin |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
As a placebo control, this formulation contains no active pharmaceutical ingredient but is manufactured to match the appearance, taste, and physical properties of dapagliflozin tablets to maintain blinding in clinical trials. Dapagliflozin itself works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, allowing filtered glucose to be excreted in urine rather than reabsorbed into the bloodstream.
Approved indications
- Placebo control for dapagliflozin clinical trials
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching Dapaglifolzin CI brief — competitive landscape report
- Placebo matching Dapaglifolzin updates RSS · CI watch RSS
- University Hospital Tuebingen portfolio CI